Printer Friendly

AVECOR CARDIOVASCULAR REPORTS THIRD QUARTER RESULTS

 AVECOR CARDIOVASCULAR REPORTS THIRD QUARTER RESULTS
 MINNEAPOLIS, Nov. 12 /PRNewswire/ -- AVECOR Cardiovascular Inc.


(NASDAQ: AVEC) today reported a net loss of $89,979, or 1 cent per share, for the three months ended September 30, 1992, compared with a loss of $18,358, or 1 cent per share, in the 1991 third quarter. Net sales were $2,877,193, compared with sales of $2,343,270 in the same period a year ago.
 For the nine months, the company reported a net loss of $41,996, or 1 cent per share, on net sales of $8,626,906. The company commenced operations in the second quarter of 1991, and thus had less than four months of activity in its first three quarters last year. Net sales for that period in 1991 were $2,912,695, with a loss of $24,217, or 1 cent per share.
 Anthony Badolato, president and chief executive officer, said, "Our current products continue to provide a solid revenue stream, with slight volume increases coming from sales of the MYOtherm cardioplegia delivery system introduced last year. We're also benefiting from price increases implemented on certain product lines in the second quarter. We continue to aggressively expand research and development, spending approximately $1.2 million year-to-date, including $545,000 in the third quarter, to broaden and improve our proprietary line of disposable medical devices. As planned, we expect resulting losses to continue into 1993."
 AVECOR Cardiovascular Inc., headquartered in Minneapolis, develops, manufactures and markets specialty disposable medical devices for heart/lung bypass surgery and long-term respiratory support. The company's current products include membrane oxygenators, cardiotomy reservoirs and cardioplegia systems.
 AVECOR Cardiovascular Inc.
 Three Months Ended Nine months Ended
 Sept. 30, Sept. 30,
 1992 1991 1992 1991
 Net sales $2,877,193 $2,343,270 $8,626,906 $2,912,695
 Net (loss) (89,979) (18,358) (41,996) (24,217)
 (Loss) per share $(.01) $(.01) $(.01) $(.01)
 Common and common
 equivalent shares
 outstanding 6,193,350 1,922,959 5,515,430 1,922,959
 -0- 11/12/92
 /CONTACT: John Swenson of Swenson Falker Eilertsen, 612-371-0000, for AVECOR; or Norman McGibbon of AVECOR, 612-559-9504/
 (AVEC) CO: AVECOR Cardiovascular Inc. ST: Minnesota IN: MTC SU: ERN


AL -- MN013 -- 0378 11/12/92 16:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 12, 1992
Words:378
Previous Article:RAYTHEON WINS $35 MILLION ARMY CONTRACT FOR SATELLITE TERMINALS
Next Article:FIFTY YEARS OF NUCLEAR TECHNOLOGY TO BE MARKED AT ANS/ENS INTERNATIONAL MEETING IN CHICAGO
Topics:


Related Articles
AVECOR CARDIOVASCULAR REPORTS FIRST QUARTER PROFIT
AVECOR CARDIOVASCULAR REPORTS SECOND QUARTER RESULTS
AVECOR CARDIOVASCULAR REPORTS SECOND QUARTER RESULTS
AVECOR CARDIOVASCULAR REPORTS FOURTH QUARTER, YEAR-END RESULTS
AVECOR CARDIOVASCULAR REPORTS FIRST QUARTER RESULTS AND ANNOUNCES SUBMISSION OF NEW OXYGENATOR TO FDA
AVECOR CARDIOVASCULAR REPORTS SECOND QUARTER LOSS
AVECOR CARDIOVASCULAR REPORTS THIRD QUARTER LOSS
AVECOR CARDIOVASCULAR REPORTS LOSS NARROWED IN 1ST QUARTER OF 1994
AVECOR Cardiovascular Reports 2nd Quarter Earnings
AVECOR Cardiovascular Reports 3rd Quarter Earnings

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters